54.85
price down icon10.24%   -6.26
pre-market  プレマーケット:  55.40   0.55   +1.00%
loading
前日終値:
$61.11
開ける:
$61.11
24時間の取引高:
658.88K
Relative Volume:
0.68
時価総額:
$1.12B
収益:
$90.12M
当期純損益:
$-276.06M
株価収益率:
-37.57
EPS:
-1.46
ネットキャッシュフロー:
$-193.47M
1週間 パフォーマンス:
-9.11%
1か月 パフォーマンス:
-15.52%
6か月 パフォーマンス:
+6,787%
1年 パフォーマンス:
+4,548%
1日の値動き範囲:
Value
$54.65
$61.40
1週間の範囲:
Value
$54.65
$66.86
52週間の値動き範囲:
Value
$0.432
$66.92

Nektar Therapeutics Stock (NKTR) Company Profile

Name
名前
Nektar Therapeutics
Name
セクター
Healthcare (1132)
Name
電話
(415) 482-5300
Name
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
職員
61
Name
Twitter
@nektarnews
Name
次回の収益日
2025-03-12
Name
最新のSEC提出書
Name
NKTR's Discussions on Twitter

NKTR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
NKTR
Nektar Therapeutics
54.85 1.24B 90.12M -276.06M -193.47M -1.46
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
433.15 107.98B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
742.00 78.84B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.93 60.05B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
915.36 55.10B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
206.60 45.09B 447.02M -1.18B -906.14M -6.1812

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-11-26 開始されました Citigroup Buy
2025-06-24 繰り返されました BTIG Research Buy
2025-06-24 繰り返されました H.C. Wainwright Buy
2025-04-11 アップグレード Jefferies Hold → Buy
2025-03-14 アップグレード Oppenheimer Perform → Outperform
2025-01-08 開始されました B. Riley Securities Buy
2024-12-10 開始されました H.C. Wainwright Buy
2024-11-04 開始されました Piper Sandler Overweight
2024-09-30 再開されました BTIG Research Buy
2024-06-28 開始されました Rodman & Renshaw Buy
2023-11-20 再開されました JP Morgan Underweight
2023-11-09 アップグレード TD Cowen Market Perform → Outperform
2023-05-10 アップグレード Jefferies Underperform → Hold
2023-02-24 ダウングレード Jefferies Hold → Underperform
2022-08-08 ダウングレード JP Morgan Neutral → Underweight
2022-05-31 再開されました Jefferies Hold
2022-04-18 ダウングレード Goldman Neutral → Sell
2022-03-15 ダウングレード Cowen Outperform → Market Perform
2022-03-15 ダウングレード Mizuho Buy → Neutral
2022-03-14 ダウングレード BTIG Research Buy → Neutral
2022-03-14 ダウングレード BofA Securities Neutral → Underperform
2022-03-14 ダウングレード Stifel Buy → Hold
2022-03-14 ダウングレード William Blair Outperform → Mkt Perform
2022-03-09 アップグレード Oppenheimer Perform → Outperform
2021-11-08 アップグレード The Benchmark Company Hold → Buy
2021-09-10 開始されました BofA Securities Neutral
2021-06-28 アップグレード Stifel Hold → Buy
2021-05-18 再開されました Goldman Neutral
2021-02-22 ダウングレード The Benchmark Company Buy → Hold
2021-01-06 開始されました Stifel Hold
2020-09-14 開始されました JP Morgan Neutral
2020-06-10 ダウングレード CFRA Hold → Sell
2020-05-12 繰り返されました H.C. Wainwright Neutral
2020-04-22 開始されました The Benchmark Company Buy
2020-03-30 アップグレード Goldman Sell → Neutral
2020-03-04 開始されました Barclays Overweight
2020-02-03 アップグレード Mizuho Neutral → Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-08 ダウングレード Goldman Buy → Sell
2019-08-09 ダウングレード JP Morgan Overweight → Neutral
2019-08-09 ダウングレード Jefferies Buy → Hold
2019-08-09 ダウングレード Mizuho Buy → Neutral
2019-03-15 開始されました SVB Leerink Mkt Perform
2018-12-13 開始されました Goldman Buy
2018-06-11 ダウングレード H.C. Wainwright Buy → Neutral
2018-06-04 繰り返されました H.C. Wainwright Buy
2018-04-20 開始されました Seaport Global Securities Buy
2018-04-13 再開されました Piper Jaffray Overweight
2018-04-06 繰り返されました Mizuho Buy
2018-04-02 再開されました H.C. Wainwright Buy
すべてを表示

Nektar Therapeutics (NKTR) 最新ニュース

pulisher
02:26 AM

How robust is Nektar Therapeutics (ITH0) stock financial position2025 Institutional Moves & Free Daily Entry Point Trade Alerts - Newser

02:26 AM
pulisher
02:10 AM

Is Nektar Therapeutics stock attractive for ETFs2025 Winners & Losers & Long-Term Growth Stock Strategies - Newser

02:10 AM
pulisher
01:39 AM

How strong dollar benefits Nektar Therapeutics (ITH0) stockTrade Signal Summary & Free Real-Time Market Sentiment Alerts - Newser

01:39 AM
pulisher
Dec 02, 2025

Will Nektar Therapeutics stock benefit from upcoming earnings reportsBreakout Watch & Low Drawdown Momentum Ideas - Newser

Dec 02, 2025
pulisher
Dec 02, 2025

Colorectal Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | Takeda, Genentech/Seagen, AstraZeneca and Daiichi Sankyo, Merck, Amgen, Daiichi Sankyo Company, Mirati Therapeu - Barchart.com

Dec 02, 2025
pulisher
Dec 02, 2025

ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors - The Manila Times

Dec 02, 2025
pulisher
Dec 02, 2025

ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors - GlobeNewswire Inc.

Dec 02, 2025
pulisher
Dec 02, 2025

Latex Allergy Market Covering Prime Factors and Competitive - openPR.com

Dec 02, 2025
pulisher
Dec 01, 2025

Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade - Finviz

Dec 01, 2025
pulisher
Nov 29, 2025

Nektar Therapeutics Reveals Promising Phase 2b Trial Results - MSN

Nov 29, 2025
pulisher
Nov 26, 2025

Nektar Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt

Nov 26, 2025
pulisher
Nov 26, 2025

Jefferies Maintains Nektar Therapeutics (NKTR) Buy Recommendation - Nasdaq

Nov 26, 2025
pulisher
Nov 26, 2025

Citigroup Initiates Coverage on NKTR with 'Buy' Rating | NKTR St - GuruFocus

Nov 26, 2025
pulisher
Nov 26, 2025

Jefferies Raises Nektar Therapeutics (NKTR) Price Target to $121 - GuruFocus

Nov 26, 2025
pulisher
Nov 26, 2025

Nektar Therapeutics R (ITH0.MU) Q2 FY2025 earnings call transcript - Yahoo Finance

Nov 26, 2025
pulisher
Nov 26, 2025

Nektar Therapeutics CEO sells $119,795 in shares By Investing.com - Investing.com South Africa

Nov 26, 2025
pulisher
Nov 26, 2025

Citi starts Nektar with Buy, opens ‘positive catalyst watch’ - TipRanks

Nov 26, 2025
pulisher
Nov 26, 2025

Nektar (NKTR) Receives Buy Rating with Positive Outlook from Cit - GuruFocus

Nov 26, 2025
pulisher
Nov 26, 2025

Citi Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $102 - 富途牛牛

Nov 26, 2025
pulisher
Nov 26, 2025

Nektar Therapeutics chief R&D officer sells $62,801 in stock By Investing.com - Investing.com Australia

Nov 26, 2025
pulisher
Nov 25, 2025

Nektar Therapeutics CLO Wilson sells $34,196 in shares By Investing.com - Investing.com South Africa

Nov 25, 2025
pulisher
Nov 25, 2025

Nektar Therapeutics Announces Pricing of $100 Million Public Offering (PR Newswire) - Aktiellt

Nov 25, 2025
pulisher
Nov 25, 2025

Nektar Therapeutics chief R&D officer sells $62,801 in stock - Investing.com

Nov 25, 2025
pulisher
Nov 25, 2025

Nektar Therapeutics CLO Wilson sells $34,196 in shares - Investing.com

Nov 25, 2025
pulisher
Nov 25, 2025

How Investors May Respond To Nektar Therapeutics (NKTR) Clinical Progress and Leadership Transition - simplywall.st

Nov 25, 2025
pulisher
Nov 25, 2025

Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $105 - 富途牛牛

Nov 25, 2025
pulisher
Nov 24, 2025

Nektar Therapeutics stock price target raised to $121 from $99 at Jefferies - Investing.com Nigeria

Nov 24, 2025
pulisher
Nov 24, 2025

Nektar Therapeutics (NKTR) PT Raised to $121 at Jefferies - StreetInsider

Nov 24, 2025
pulisher
Nov 24, 2025

Assessing Nektar Therapeutics (NKTR) Valuation Following Recent Share Price Surge - simplywall.st

Nov 24, 2025
pulisher
Nov 23, 2025

Nektar Therapeutics Stock Analysis and ForecastInsider Buying Signals & Stay One Step Ahead of Risk Events - earlytimes.in

Nov 23, 2025
pulisher
Nov 23, 2025

Is Nektar Therapeutics (NKTR) The Hottest SMID-Cap Stock to Buy Now? - Finviz

Nov 23, 2025
pulisher
Nov 21, 2025

Nektar Therapeutics announces chief legal officer transition effective year-end By Investing.com - Investing.com India

Nov 21, 2025
pulisher
Nov 21, 2025

Nektar Therapeutics Announces Chief Legal Officer Departure - TipRanks

Nov 21, 2025
pulisher
Nov 21, 2025

Nektar Therapeutics announces chief legal officer transition effective year-end - Investing.com

Nov 21, 2025
pulisher
Nov 21, 2025

Nektar Therapeutics Announces Chief Legal Officer Change - TradingView

Nov 21, 2025
pulisher
Nov 21, 2025

Rezpegaldesleukin Shows Strong Phase 2b Results for Atopic Dermatitis, Asthma - HCPLive

Nov 21, 2025
pulisher
Nov 21, 2025

Can Nektar Therapeutics (ITH0) stock stage a strong rebound this quarterMarket Risk Summary & Daily Market Momentum Tracking - newser.com

Nov 21, 2025
pulisher
Nov 21, 2025

Will Nektar Therapeutics (ITH0) stock beat Nasdaq index returns2025 Investor Takeaways & AI Enhanced Trading Signals - newser.com

Nov 21, 2025
pulisher
Nov 20, 2025

Nektar at Jefferies: Biologics in Focus for New Indications By Investing.com - Investing.com Australia

Nov 20, 2025
pulisher
Nov 20, 2025

Nektar at Jefferies: Biologics in Focus for New Indications - Investing.com

Nov 20, 2025
pulisher
Nov 20, 2025

Nektar Therapeutics (NKTR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 20, 2025
pulisher
Nov 20, 2025

How big funds are accumulating Nektar Therapeutics (ITH0) stockMarket Rally & Long-Term Safe Investment Ideas - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Will Nektar Therapeutics (ITH0) stock profit from fiscal stimulusWeekly Risk Summary & AI Optimized Trading Strategy Guides - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Is Nektar Therapeutics stock attractive for passive investorsJuly 2025 EndofMonth & AI Powered Trade Plan Recommendations - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

How Nektar Therapeutics (ITH0) stock trades in high volatilityMarket Risk Analysis & Safe Entry Zone Tips - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

What RSI levels show for Nektar Therapeutics (ITH0) stock2025 Major Catalysts & Capital Efficiency Focused Strategies - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Is it time to cut losses on Nektar TherapeuticsJuly 2025 Highlights & Verified Entry Point Signals - newser.com

Nov 20, 2025

Nektar Therapeutics (NKTR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$39.53
price down icon 0.93%
$101.44
price down icon 0.59%
$31.71
price up icon 1.02%
$96.11
price down icon 1.31%
biotechnology ONC
$330.19
price down icon 1.61%
$206.60
price down icon 2.28%
大文字化:     |  ボリューム (24 時間):